P/B
3,9
Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
$10.6B
Market Cap • 10/9/2026
2013
(13 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
18,5
EPS
—
Market Cap
Market Cap
10,6B
EV
9,3B
EV/Revenue
0
EV/EBITDA
-8,1
EV/EBIT
-7,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-5,7%
Total Yield
-5,7%
Payout
0%
Retained Earnings
-2,8B
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
148,8%
Capex/OCF
-4,5%
SBC/OCF
—
% PPE
11,8%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
67,8%
CAGR Net Income 5Y
65,1%
CAGR EPS 5Y
35,2%
CAGR OCF 5Y
68,1%
Leverage
N.D./EBITDA
1,2
Debt/Equity
0%
Current Ratio
5,7
Quick Ratio
5,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!